Read an up-to-date overview of our activities and the financial statement for 2019.
2019, our twentieth year, gave MMV and our partners many reasons to celebrate. Established in 1999 to reignite stalled research and development into malaria medicines, MMV has since built the richest malaria drug pipeline in history, with 13 new antimalarials now treating patients. These medicines have contributed to saving more than 2.2 million lives and are helping ‘bend the curve’ towards the eradication of malaria.
Bending the curve to malaria eradication
Improving case management of uncomplicated malaria
Protecting those most at risk
Scaling up access to life-saving interventions for severe malaria
Reducing the burden of relapsing malaria
R&D platforms and drug discovery
Enriching the drug discovery pipeline with an "irresistible" compound
Behind the scenes